MOLECULAR MARKERS OF CERVICOVAGINAL FLUID: NOVELTY IN THE DIAGNOSIS AND PREDICTION OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To make a systematic analysis of the data available in the present-day literature on the value of molecular markers of cervicovaginal fluid in the diagnosis of human papillomavirus-(HPV)-assoctated cervical diseases and to present prospects for investigating the proteomic and metabolomic profiles of cervicovaginal fluid to predict the course of neoplastic processes in the cervix uteri. Subject and methods. The review included the data of theforeign and Russian articles published in the past 5 years, which had been found in Pubmed on this topic. Results. A number of proteomic markers of cervicovaginal fluid for the early diagnosis of precancerous diseases and cancer of the cervix uteri were described. Conclusion. There is a needfor further studies for the identification of specific molecular genetic and proteomic markers of cervicovaginalfluid, for the early diagnosis and prediction of the course of HPV- associated cervical diseases.

Full Text

Restricted Access

About the authors

Maka Djemalovna Zardiashvili

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: z-m-d@mail.ru
PhD student Moscow 117997, Ac. Oparina str. 4, Russia

Niso Mirzoevna Nazarova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: grab2@yandex.ru
MD, PhD, Senior Researcher Moscow 117997, Ac. Oparina str. 4, Russia

Nataliia Leonidovna Starodubtseva

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: n_starodubtseva@oparina4.ru
PhD, Head of Laboratory of Proteomics of Human Reproduction Moscow 117997, Ac. Oparina str. 4, Russia

Anna Evgenievna Bugrova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: a_bugrova@oparina4.ru
PhD, Senior Researcher of Proteomics of Human Reproduction Moscow 117997, Ac. Oparina str. 4, Russia

Vladimir Evgenievich Frankevich

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: v_frankevich@oparina4.ru
PhD, Head of Department of Systems Biology in Reproduction Moscow 117997, Ac. Oparina str. 4, Russia

Vera Nikolaevna Prilepskaya

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: VPrilepskaya@mail.ru
MD, Professor, Deputy Director for Science Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Zur Hausen Н. Human genital cancer: Synergism between two virus infections or synergism between a virus infection and initiating events? Lancet. 1982; 2(8312): 1370-2.
  2. Zur Hausen H Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 2000; 92(9): 690-8.
  3. Ашрафян Л.А., Киселев В.И. Опухоли репродуктивных органов (этиология и патогенез). М.: Дмитрейд График Групп; 2008. 216с.
  4. Прилепская B.H., ред. Заболевания шейки матки, влагалища, вульвы. М.: МЕДпресс-информ; 2005.432с. [Prilepskaya V.N., eds. Diseases of the cervix, vagina, vulva. Moscow: MEDpress-Inform; 2005. 432p. (in Russian)].
  5. Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки: в помощь практикующему врачу. 2-е изд. М.: ГЭОТАР. Медиа; 2014. 208с.
  6. Рекомендации по диагностике и лечению папилломавирусных инфекций женского генитального тракта. Официальная публикация Европейского Общества по инфекционным заболеваниям в акушерстве и гинекологии // European J. Inr. Immunol. Dis. Obstet. Gynaecol. 2001; vol. 4, 5. Suppl. 21. Уточн. где опубл.
  7. Von Knebel-Doeberitz M. New markers for cervical dysplasia to visualize the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur. J. Cancer. 2002; 38(17): 2229-42.
  8. Wheeler C.M., Hunt W.C., Schiffman M., Castle RE. Human papillomavirus genotypes and the cumulative 2-years risk of cervical precancer. J. Infect. Dis. 2006; 194(9): 1291-9.
  9. Van Raemdonck G.A., Tjalma WA., Coen E.P., Depuydt C.E., Van Ostade X.W. Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid. PLoS One. 2014; 9(9): ЄІ06488.
  10. http://www.cdc.gov/hpv
  11. Ullal A., Roberts M., Bulmer J.N., Mathers M.E., Wadehra V. The role of cervical cytology and colposcopy in detecting cervical glandular neoplasia. Cytopathology. 2008; 20(6): 359-66.
  12. Pereira P.M., Marques J.P., Soares A.R., Carreto L., Santos MA. MicroRNA expression variability in human cervical tissues. PLoS One. 2010; 5(7): el 1780.
  13. Quayle A.J. The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells. J. Reprod. Immunol. 2002; 57(1-2): 61-79.
  14. Cole A.M. Innate host defense of human vaginal and cervical mucosae. Curr. Top. Microbiol. Immunol. 2006; 306: 199-230.
  15. Ochiel D.O., Fahey J.V., Ghosh M., Haddad S.N., Wira C.R. Innate immunity in the female reproductive tract: role of sex hormones in regulating uterine epithelial cell protection against pathogens. Cur.r Womens Health Rev. 2008, 4(2): 102-17.
  16. Jijima N., Thompson J.M., Iwasaki A. Dendritic cells and macrophages in the genitourinary tract. Mucosal Immunol. 2008; 1(6): 451-9.
  17. Eschenbach D.A., Thwin S.S., Patton D.L., Hooton T.M., Stapleton A.E., Agnew K. et al. Influence of the normal menstrual cycle on vaginal tissue, discharge, and microflora. Clin. Infect. Dis. 2000; 30(6): 901-7.
  18. Valore E.V., Park C.H., Igreti S.L., Ganz T. Antimicrobial components of vaginal fluid. Am. J. Obstet. Gynecol. 2002; 187(3): 561-8.
  19. Rohan L.C., Sassi A.B. Vaginal drug delivery systems for HIV prevention. AAPS J. 2009; 11(1): 78-87.
  20. Wira C.R., Grant-Tschudy K.S., Crane-Godreau M.A. Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am. J. Reprod. Immunol. 2005; 53(1): 65-76.
  21. Klein L.L., Jonscher K.R., Heerwagen M.J., Gibbs R.S., McManaman J.L. Shotgun proteomic analysis of vaginal fluid from women in late pregnancy. Reprod. Sci. 2008; 15(3): 263-73.
  22. Zegels G., Van Raemdonck G.A., Tjalma W.A., Van Ostade X.W. Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract. Proteome Sci. 2010; 8: 63.
  23. Thomas P.D., Campbell M.J., Kejariwal A., Mi H, KarlakB., Daverman R. et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003; 13(9): 2129-41.
  24. Good D.M., Thongboonkerd V, Novak J., Bascands J.L., Schanstra J.P., Coon J.J. et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J. Proteome Res. 2007; 6(12): 4549-55.
  25. Veenstra T.D., Conrads T.P., HoodB.L., Avellino A.M., Ellenbogen R.G., Morrison R.S. Biomarkers: mining the biofluid proteome. Mol. Cell. Proteomics. 2005; 4(4): 409-18.
  26. Hu S., Loo J.A., Wong D. T. Human body fluid proteome analysis. Proteomics. 2006; 6(23): 6326-53.
  27. Schmidt A., Aebersold R. High-accuracy proteome maps of human body fluids. Genome Biol. 2006; 7(11): 242.
  28. Balu R.B., Savitz D.A., Ananth C.V., Hartmann K.E., Miller W.C., Thorp J.M., Heine R.P. Bacterial vaginosis, vaginal fluid neutrophil defensins, and preterm birth. Obstet. Gynecol. 2003; 101(5, Ptl): 862-8.
  29. NovakR.M., DonovalB.A., Graham P.J., Boksa L.A., Spear G., Hershow R. C. et al. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin. Vaccine Immunol. 2007; 14(9): 1102-7.
  30. Wiesenfeld H.C., Heine R.P., Krohn M.A., Hillier S.L., Amortegui A.A., Nicolazzo M., Sweet R.L. Association between elevated neutrophil defensin levels and endometritis. J. Infect. Dis. 2002; 186(6): 792-7.
  31. Xu J., Holzman C.B., Arvidson C.G., Chung H., Goepfert A.R. Midpregnancy vaginal fluid defensins, bacterial vaginosis, and risk of preterm delivery. Obstet. Gynecol. 2008; 112(3): 524-31.
  32. St John E., Mares D., Spear G. T. Bacterial vaginosis and host immunity. Curr. HIV/AIDS Rep. 2007; 4(1): 22-8.
  33. Spear G.T., St John E., Zariffard M.R. Bacterial vaginosis and human immunodeficiency virus infection. AIDS Res. Ther. 2007; 4: 25.
  34. Wira C.R., Fahey J.V. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS. 2008; 22(15): 1909-17.
  35. Meng W., Du R., Wang Y, Chen Z., Ding Y. Human [3-defensin messenger RNA is overexpressed in the cervical epithelia of patients with nongonococcal cervicitis. J. Low Genit. Tract. Dis. 2013; 17(4): 440-5.
  36. Shimoya K., Zhang Q., Temma K., Kimura I, Tsujie T, Tsutsui T. et al. Secretory leukocyte protease inhibitor levels in cervicovaginal secretion of elderly women. Maturitas. 2006; 54(2): 141-8.
  37. Cherpes T.L., Marrazzo J.M., Cosentino L.A., Meyn L.A., Murray P.J., Hillier S.L. Hormonal contraceptive use modulates the local inflammatory response to bacterial vaginosis. Sex. Transm. Infect. 2008; 84(1): 57-61.
  38. Ildgruben A., Sjoberg I., Hammarstrom M.L., Backstrom T. Steroid receptor expression in vaginal epithelium of healthy fertile women and influences of hormonal contraceptive usage. Contraception. 2005; 72(5): 383-92.
  39. Ildgruben A.K, Sjoberg I.M., Hammarstrom M.L. Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet. Gynecol. 2003; 102(3): 571-82.
  40. Venkataraman N., Cole A.L., Svoboda R, Pohl J., Cole A.M. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J. Immunol. 2005; 175(11): 7560-7.
  41. Di Quinzjo M.K., Oliva K., Holdsworth S.J., Ayhan M., Walker S.P., Rice G.E. et al. Proteomic analysis and characterisation of human cervico-vaginal fluid proteins. Aust. N. Z. J. Obstet. Gynaecol. 2007; 47(1): 9-15.
  42. Heng Y.J., Di Quinzio M.K., PermezelM., Rice G.E., Georgiou H.M. Interleukin-1 receptor antagonist in human cervicovaginal fluid in term pregnancy and labor. Am. J. Obstet. Gynecol. 2008; 199(6): 656-73. el-7.
  43. Dasari S., Pereira L., Reddy A.P., Michaels J.E., Lu X., Jacob T. et al. Comprehensive proteomic analysis of human cervical-vaginal fluid. J. Proteome Res. 2007; 6(4): 1258-68.
  44. Shaw J.L., Smith C.R., Diamandis E.P. Proteomic analysis of human cervicovaginal fluid. J. Proteome Res. 2007; 6(7): 2859-65.
  45. Tang L.J., De S.F., Odreman E, Venge P, Piva C, Guaschino S., Garcia R.C. Proteomic analysis of human cervical-vaginal fluids. J. Proteome Res. 2007; 6(7): 2874-83.
  46. Zegels G., Van Raemdonck G.A., Coen E.P, Tjalma W.A., Van Ostade X.W. Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples. Proteome Sci. 2009; 7:17.
  47. Andersch-Bjorkman Y., Thomsson К A., Holmen Larsson J.M., Ekerhovd E., Hansson G.C. Large scale identification of proteins, mucins, and their O-glycosylation in the endocervical mucus during the menstrual cycle. Mol. Cell. Proteomics. 2007; 6(4): 708-16.
  48. Panicker G., Ye Y, WangD., Unger E.R. Characterization of the human cervical mucous proteome. Clin. Proteomics. 2010; 6(1-2): 18-28.
  49. Ding T, Wang X., Ye E, Cheng X., Ma D., Lu W., Xie X. Distribution of human papillomavirus 58 and 52 E6/E7 variants in cervical neoplasia in Chinese women. Gynecol. Oncol. 2010; 119(3): 436-43.
  50. Van Ostade X., Martin Dorn, Van Raemdonck G. IPA. Analysis of cervicovaginal fluid from precancerous women points to the presence of biomarkers for the precancerous state of cervical carcinoma. Proteomes. 2014; 2(3): 426-50. doi: 10.3390/proteomes2030426.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies